Idelvion

Riik: Euroopa Liit

keel: inglise

Allikas: EMA (European Medicines Agency)

Osta kohe

Infovoldik Infovoldik (PIL)
18-09-2023
Toote omadused Toote omadused (SPC)
18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
27-05-2016

Toimeaine:

albutrepenonacog alfa

Saadav alates:

CSL Behring GmbH

ATC kood:

B02BD04

INN (Rahvusvaheline Nimetus):

albutrepenonacog alfa

Terapeutiline rühm:

Antihemorrhagics

Terapeutiline ala:

Hemophilia B

Näidustused:

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

Toote kokkuvõte:

Revision: 12

Volitamisolek:

Authorised

Loa andmise kuupäev:

2016-05-11

Infovoldik

                                42
B. PACKAGE LEAFLET
43
PACKAGE LEAFLET: INFORMATION FOR THE USER
IDELVION 250 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
IDELVION 500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
IDELVION 1000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
IDELVION 2000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
IDELVION 3500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
albutrepenonacog alfa (recombinant coagulation factor IX)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have further questions, ask your doctor, pharmacist or nurse.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.

If you get any side effects talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What IDELVION is and what it is used for
2.
What you need to know before you use IDELVION
3.
How to use IDELVION
4.
Possible side effects
5.
How to store IDELVION
6.
Contents of the pack and other information
1.
WHAT IDELVION IS AND WHAT IT IS USED FOR
WHAT IS IDELVION?
IDELVION is a haemophilia medicine that replaces a natural blood
clotting (coagulation) factor IX.
The active substance in IDELVION is albutrepenonacog alfa (recombinant
fusion protein linking
coagulation factor IX with albumin (rIX-FP)).
Factor IX is involved in blood clotting. Patients with haemophilia B
have a lack of this factor which
means that their blood does not clot as quickly as it should so there
is an increased tendency to bleed.
IDELVION works by replacing factor IX in haemophilia B patients to
enable their blood to clot.
WHAT IS IDELVION USED FOR?
IDELVION is used to prevent or to halt bleeding caused by the lack of
factor IX in patients of all age
groups with haemophilia B (also called congenital factor IX deficiency
or Christ
                                
                                Lugege kogu dokumenti
                                
                            

Toote omadused

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
IDELVION 250 IU powder and solvent for solution for injection
IDELVION 500 IU powder and solvent for solution for injection
IDELVION 1000 IU powder and solvent for solution for injection
IDELVION 2000 IU powder and solvent for solution for injection
IDELVION 3500 IU powder and solvent for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
IDELVION 250 IU powder and solvent for solution for injection
Each vial contains nominally 250 IU of recombinant fusion protein
linking coagulation factor IX with
albumin (rIX-FP), (albutrepenonacog alfa). After reconstitution with
2.5 ml water for injections the
solution contains 100 IU/ml of albutrepenonacog alfa.
IDELVION 500 IU powder and solvent for solution for injection
Each vial contains nominally 500 IU of recombinant fusion protein
linking coagulation factor IX with
albumin (rIX-FP), (albutrepenonacog alfa). After reconstitution with
2.5 ml water for injections the
solution contains 200 IU/ml of albutrepenonacog alfa.
IDELVION 1000 IU powder and solvent for solution for injection
Each vial contains nominally 1000 IU of recombinant fusion protein
linking coagulation factor IX with
albumin (rIX-FP), (albutrepenonacog alfa). After reconstitution with
2.5 ml water for injections the
solution contains 400 IU/ml of albutrepenonacog alfa.
IDELVION 2000 IU powder and solvent for solution for injection
Each vial contains nominally 2000 IU of recombinant fusion protein
linking coagulation factor IX with
albumin (rIX-FP), (albutrepenonacog alfa). After reconstitution with 5
ml water for injections the
solution contains 400 IU/ml of albutrepenonacog alfa.
IDELVION 3500 IU powder and solvent for solution for injection
Each vial contains nominally 3500 IU of recombinant fusion protein
linking coagulation factor IX with
albumin (rIX-FP), (albutrepenonacog alfa). After reconstitution with 5
ml water for injections the
solution contains 700 IU/ml of albutrepenonacog alfa.
The potency (IU) is
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik bulgaaria 18-09-2023
Toote omadused Toote omadused bulgaaria 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande bulgaaria 27-05-2016
Infovoldik Infovoldik hispaania 18-09-2023
Toote omadused Toote omadused hispaania 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande hispaania 27-05-2016
Infovoldik Infovoldik tšehhi 18-09-2023
Toote omadused Toote omadused tšehhi 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande tšehhi 27-05-2016
Infovoldik Infovoldik taani 18-09-2023
Toote omadused Toote omadused taani 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande taani 27-05-2016
Infovoldik Infovoldik saksa 18-09-2023
Toote omadused Toote omadused saksa 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande saksa 27-05-2016
Infovoldik Infovoldik eesti 18-09-2023
Toote omadused Toote omadused eesti 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande eesti 27-05-2016
Infovoldik Infovoldik kreeka 18-09-2023
Toote omadused Toote omadused kreeka 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande kreeka 27-05-2016
Infovoldik Infovoldik prantsuse 18-09-2023
Toote omadused Toote omadused prantsuse 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande prantsuse 27-05-2016
Infovoldik Infovoldik itaalia 18-09-2023
Toote omadused Toote omadused itaalia 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande itaalia 27-05-2016
Infovoldik Infovoldik läti 18-09-2023
Toote omadused Toote omadused läti 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande läti 27-05-2016
Infovoldik Infovoldik leedu 18-09-2023
Toote omadused Toote omadused leedu 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande leedu 27-05-2016
Infovoldik Infovoldik ungari 18-09-2023
Toote omadused Toote omadused ungari 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande ungari 27-05-2016
Infovoldik Infovoldik malta 18-09-2023
Toote omadused Toote omadused malta 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande malta 27-05-2016
Infovoldik Infovoldik hollandi 18-09-2023
Toote omadused Toote omadused hollandi 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande hollandi 27-05-2016
Infovoldik Infovoldik poola 18-09-2023
Toote omadused Toote omadused poola 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande poola 27-05-2016
Infovoldik Infovoldik portugali 18-09-2023
Toote omadused Toote omadused portugali 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande portugali 27-05-2016
Infovoldik Infovoldik rumeenia 18-09-2023
Toote omadused Toote omadused rumeenia 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande rumeenia 27-05-2016
Infovoldik Infovoldik slovaki 18-09-2023
Toote omadused Toote omadused slovaki 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande slovaki 27-05-2016
Infovoldik Infovoldik sloveeni 18-09-2023
Toote omadused Toote omadused sloveeni 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande sloveeni 27-05-2016
Infovoldik Infovoldik soome 18-09-2023
Toote omadused Toote omadused soome 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande soome 27-05-2016
Infovoldik Infovoldik rootsi 18-09-2023
Toote omadused Toote omadused rootsi 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande rootsi 27-05-2016
Infovoldik Infovoldik norra 18-09-2023
Toote omadused Toote omadused norra 18-09-2023
Infovoldik Infovoldik islandi 18-09-2023
Toote omadused Toote omadused islandi 18-09-2023
Infovoldik Infovoldik horvaadi 18-09-2023
Toote omadused Toote omadused horvaadi 18-09-2023
Avaliku hindamisaruande Avaliku hindamisaruande horvaadi 27-05-2016

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu